---
schema_version: "secwatch.filing_event.v1"
accession: "0001680367-24-000038"
form_type: "8-K"
ticker: "STTK"
cik: "0001680367"
company_name: "Shattuck Labs, Inc."
filed_at: "2024-08-01T23:59:59+00:00"
generated_at: "2026-05-31T13:51:59.552066+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Shattuck Labs Q2 net loss $21.5M; SL-172154 shows 67% ORR in HR-MDS trial

## Summary
- Net loss $21.5M ($0.42 per share) vs $21.3M ($0.50 per share) Q2 2023.
- Cash and investments $105.3M as of June 30, 2024, down from $117.2M a year ago.
- SL-172154 in frontline HR-MDS: 67% ORR, 58% CR/marrow CR rate; median OS not reached.
- Randomized Part D enrollment initiated in frontline HR-MDS (1:1:1 vs AZA alone).
- Cash runway into 2026, beyond Phase 1 trial results.

## SEC filing metadata
- accession: 0001680367-24-000038
- form_type: 8-K
- ticker: STTK
- cik: 0001680367
- company_name: Shattuck Labs, Inc.
- filed_at: 2024-08-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680367/000168036724000038/0001680367-24-000038-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680367/000168036724000038/sttk-20240801.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001680367-24-000038
- JSON: https://secwatch.observer/filing/0001680367-24-000038.json
- Plain text: https://secwatch.observer/filing/0001680367-24-000038.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.